Canine Atopic Dermatitis Market Size & Share 2026-2035

Canine Atopic Dermatitis Market Size

The global canine atopic dermatitis market was estimated at USD 1.5 billion in 2025. The market is expected to grow from USD 1.6 billion in 2026 to USD 3.6 billion in 2035, growing at a CAGR of 9.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market has exhibited a steady growth trend attributable to the rising incidences of atopic dermatitis in dogs and heightened focus on companion animal healthcare. The market size reflects the growing demand for advanced veterinary dermatology drugs as pet owners become more conscious of their pets' well-being.
 

One of the major driving forces for the market size is the development in veterinary medications. Innovative treatments, such as monoclonal antibodies (Lokivetmab/Cytopoint) and targeted oral therapies (Oclacitinib/Apoquel), provide safe and effective options for managing the condition. These medications have gained immense popularity because of their proven efficacy in reducing the symptoms of pruritus (itching) and inflammation, thus adding to the growing demand for these medications. Moreover, in the emerging regions, the rising disposable income and growing knowledge about companion animal healthcare are leading to investments in pet health and specialized veterinary care, thus adding to the overall market growth.
 

Canine atopic dermatitis is a genetically driven, chronic inflammatory skin disease in dogs that results from an adverse reaction to environmental allergens such as pollen, dust mites, mold, or certain foods. This disorder occurs due to an exaggerated immune system response, which causes chronic itching, redness, and recurrent skin or ear infections. It is one of the most common dermatological issues in dogs and typically manifests in predisposed breeds like Retrievers, Terriers, and Bulldogs.

Key players in this market including Zoetis, Elanco Animal Health, Virbac, Boehringer Ingelheim, and Dechra Veterinary Products dominated the market. These players are driving the market by indulging in research and development activities for innovative dermatology treatments such as monoclonal antibodies and targeted immunomodulators, which provide long-lasting relief from symptoms.
 

The atopic dermatitis market expanded from USD 1.2 billion in 2022 to USD 1.4 billion in 2024 due to the rising number of pet owners, awareness regarding the dermatological health of companion animals, and the willingness of pet owners to spend on innovative veterinary treatments. The growth was also fueled by the rising adoption of innovative therapies such as monoclonal antibodies and targeted immunomodulators, increased diagnostic rates, and improved veterinary distribution channels, especially in North America and Europe.
 

Canine Atopic Dermatitis Market Trends

The growth of the canine atopic dermatitis industry is influenced by multiple market trends, which are opening new avenues and propelling the adoption of effective treatment solutions.
 

• Rising pet ownership especially among general population in emerging countries, is one of the key factors driving the growth of the canine atopic dermatitis market.
   
• With more people and families adopting pet companionship, there is a growing demand for sophisticated veterinary care and specialized treatment for common ailments such as atopic dermatitis.
   
• For instance, based on the US & Worldwide Statistics 2026 article by Doster, it is estimated that there are 900 million pet dogs globally, which highlights the widespread use of dogs as pets.
   
• Pet owners now consider their pets as essential members of their families, resulting in increased expectations regarding their health and a desire to spend money on high-quality healthcare solutions. This has led to the acceptance of innovative healthcare solutions, such as allergen-specific immunotherapy, monoclonal antibodies, and customized dermatology products, for the treatment of atopic dermatitis in dogs.
   
• The emphasis on personalized pet care and preventive healthcare is also fueling the development of targeted solutions, which is driving the market.
   
• In addition, the incorporation of digital veterinary care, such as telemedicine consultations and mobile applications, is another emerging trend that is improving the diagnosis and treatment of pets as well as their access to specialized dermatology care.
   
• Furthermore, the development of e-commerce and online pet pharmacies is also improving access to prescription dermatology products, which is driving market adoption and expanding the market beyond veterinary practices.
   
• Moreover, the application of long-acting and targeted biologics, such as monoclonal antibodies, ensures greater symptom relief and convenience for pet owners, thus contributing to the growth of the market.
   
• Collectively, these trends are contributing to increased product adoption, innovation and sustained growth in the management of canine atopic dermatitis globally.
   

Canine Atopic Dermatitis Market Analysis

Based on the product, the canine atopic dermatitis market is segmented into glucocorticoids, antihistamines, immunosuppressants, MAbs, and other products. The glucocorticoids segment held highest market share and was valued at USD 511.6 million in 2025.
 

• Glucocorticoids, including prednisone and dexamethasone, are highly effective in providing rapid relief from inflammation and itching, making them a preferred option for managing acute and severe cases. Their widespread application as a first-line therapy positions this segment for continued growth in the coming years.
   
• Additionally, their affordability compared to newer treatments, such as monoclonal antibodies (Lokivetmab) or oral JAK inhibitors (oclacitinib), further drives their adoption, particularly in regions with limited veterinary healthcare resources or low pet insurance penetration.
   
• Furthermore, high availability of glucocorticoids across veterinary hospital pharmacies, retail pharmacies, and online platforms ensures easy access, further strengthening their market share and solidifies their role as a cornerstone treatment for canine atopic dermatitis.
   
• On the other hand, the monoclonal antibodies (MAbs) segment is anticipated to witness growth at 9.7% CAGR during the forecast period driven by increasing adoption targeted biologic therapies. These targeted biologic therapies provide long-lasting relief from symptoms, reduce dosing frequency, and enhance the safety profile compared to conventional treatments.
   
• Monoclonal antibodies are gaining preference among veterinarians and pet owners for their efficacy in managing chronic inflammatory skin conditions, further contributing to market expansion.

• Oral treatments, such as oclacitinib (Apoquel) and glucocorticoids like prednisone, are easy to administer and preferred by pet owners. This convenience enhances compliance and ensures consistent treatment, contributing to their popularity.
   
• Many oral therapies offer fast symptom relief, addressing key symptoms like pruritus and inflammation within hours to days. This makes them a preferred choice for both acute management and chronic conditions.
   
• Oral therapies have a proven track record of efficacy and safety. Medications like oclacitinib are specifically designed to target inflammatory pathways, providing effective and targeted relief, further driving their demand.
   

Based on the distribution channel, the canine atopic dermatitis market is classified into veterinary hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacies segment accounted for highest market share in 2025 and grow at 8.9% CAGR over the coming years.
 

• Retail pharmacies hold a significant market share in the market due to their widespread accessibility, ease of dispensing medications, and growing pet ownership trends.
   
• These pharmacies serve as a primary channel for distributing topical treatments, oral medications, and other prescription therapies prescribed by veterinarians for managing canine atopic dermatitis.
   
• Additionally, the increasing availability of over-the-counter products designed for atopic dermatitis, further drives the dominance of retail pharmacies in this market.
   
• On the other hand, online pharmacies segment is expected to witness growth at significant CAGR of 9.8% during the coming years.
   
• This growth is driven by increasing adoption of e-commerce platforms for veterinary products, greater accessibility to prescription dermatology treatments, and the convenience of doorstep delivery.
   
• Pet owners are increasingly leveraging online channels for purchasing medications and specialty therapies, which is expanding the reach of dermatology products beyond traditional veterinary clinics and boosting overall market growth.
   

North America Canine Atopic Dermatitis Market

The North America canine atopic dermatitis industry held the largest market share of 41% in 2025 in the market, and it is anticipated to expand at 9% CAGR over the forecast period.  
 

• The region’s market dominance is driven by the growing population of pet dogs, which has increased from an estimated 52.9 million in 1996 to 87.3 million in 2025, reflecting the rising trend of pet ownership. This increasing number of dogs along with other factors such as the humanization of pets and increasing awareness of skin disorders are driving the market size.
   
• Additionally, the widespread adoption of advanced therapies such as monoclonal antibodies and strong veterinary infrastructure with access to innovative dermatology treatments are further boosting market in North America.
   

The U.S. canine atopic dermatitis market was valued at USD 461.7 million and USD 492.8 million in 2022 and 2023, respectively. The market size reached USD 565.8 million in 2025, growing from USD 527.3 million in 2024.
 

• The U.S. canine atopic dermatitis industry holds a significant share in the global landscape, driven by the increasing prevalence of atopic dermatitis among dogs and the growing awareness of pet health among pet owners.
   
• The high adoption of advanced veterinary diagnostics and therapeutics, coupled with the robust presence of key players offering innovative treatments further propels the market.
   
• Additionally, the increasing expenditure on pet healthcare and the rising trend of premium pet care products contribute to the market's dominance.
   
• The U.S. also benefits from a well-established veterinary infrastructure and supportive regulatory frameworks, fostering the development and availability of effective treatment options.
   

Europe Canine Atopic Dermatitis Market

The Europe canine atopic dermatitis industry was valued at USD 416.5 million in 2025 and is anticipated to witness strong growth over the forecast period.
 

• The market is supported by a large dog population, which reached 90 million in 2023, according to the European Pet Food Industry. Thus, this rising pet ownership along with increasing adoption of pet insurance is driving demand for advanced dermatology treatments.
   
• Additionally, the presence of well-structured veterinary networks, adoption of innovative therapies such as monoclonal antibodies, and the development of online veterinary pharmacies and telemedicine services are further increasing accessibility and adoption of treatments in Europe.
   

Germany canine atopic dermatitis market is anticipated to witness lucrative growth over coming years.
 

• Germany is home to a thriving pharmaceutical industry with a focus on veterinary medicine, ensuring consistent R&D efforts, product innovation, and efficient distribution networks for therapies.
   
• Additionally, the favorable government regulations and strict guidelines for veterinary treatments in the country provide a guarantee for the use of safe and effective treatments, thereby promoting market growth.
   
• The increasing emphasis on pets' well-being, coupled with the strong bond between owners and their dogs, supports higher spending on dermatological treatments like canine atopic dermatitis management.
   

Asia Pacific Canine Atopic Dermatitis Market

Asia Pacific canine atopic dermatitis industry is expected to grow with considerable growth rate of 9.5% over the coming years, driven by increasing pet dog populations and rising demand for specialized veterinary care.
 

• In India alone, the number of pet dogs has crossed 33 million in 2023 and is projected to reach over 51 million by 2028, indicating an increasing market base. The substantial increase in the number of pet dogs indicates a rapidly growing market opportunity for the market in this region.
   
• Furthermore, the increasing emphasis on preventive healthcare and wellness for pet animals in this region is encouraging the use of novel management approaches for canine atopic dermatitis.
   

China is expected to register growth at significant rate during the forecast period.
 

• The increasing middle class in China, with increased disposable income, allows more pet owners to access advanced treatments for canine atopic dermatitis, such as novel approaches like monoclonal antibodies and oral JAK inhibitors.
   
• The development of online veterinary pharmacies and e-commerce platforms makes it easily accessible to medications, which increases the availability of advanced treatments in rural and urban areas.
   

Latin America Canine Atopic Dermatitis Market

Brazil's canine atopic dermatitis industry is expected to showcase significant growth over the analysis period in Latin America market.
 

• Brazil has the second-largest number of pet dogs in the world, due to the culture of pet companionship. Rising pet dog ownership translates to an increase in the demand for pet healthcare services, such as the treatment of canine atopic dermatitis.
   
• Moreover, the rising trend of humanizing pets has resulted in rising expenditures on pet healthcare, such as dermatological disorders like canine atopic dermatitis.
   

Middle East and Africa Canine Atopic Dermatitis Market

Saudi Arabia canine atopic dermatitis industry is expected to grow in the coming years in the overall Middle East and Africa market.
 

• The rising affluence of the Saudi Arabian population, along with the growing practice of treating pets as family members, is leading to increased spending on pet healthcare, including the treatment of chronic diseases such as canine atopic dermatitis.
   
• Furthermore, the growing popularity of e-commerce platforms that deal with the sale of veterinary products and medications is making treatment available to pet owners in Saudi Arabia. Thus, these factors together aid in driving the Saudi Arabia canine atopic dermatitis industry.
   

Canine Atopic Dermatitis Market Share

The canine atopic dermatitis industry is characterized by the presence of numerous global and regional pharmaceutical companies. Key players including Zoetis, Elanco Animal Health, Virbac, Boehringer Ingelheim, and Dechra Veterinary Products accounted for 62.7% of market share. These players are actively involved in the development of innovative treatments for CAD, such as monoclonal antibodies (e.g., Lokivetmab) and JAK inhibitors (e.g., Oclacitinib). These companies are leveraging partnerships, research collaborations, and mergers and acquisitions to enhance their product portfolios and expand their market reach.
 

In addition, these key players are increasingly focusing on digital initiatives and e-commerce channels to improve accessibility and convenience for pet owners. They are also investing in veterinarian education programs and awareness campaigns to promote early diagnosis and proper management of canine atopic dermatitis. Continuous innovation in long-acting therapies, breed-specific treatments, and personalized dermatology solutions further strengthens their competitive positioning, enabling sustained market growth and higher adoption of advanced therapeutic options globally.
 

Canine Atopic Dermatitis Market Companies

Prominent players operating in the canine atopic dermatitis industry include:

• AB Science
• Boehringer Ingelheim
• Ceva
• Dechra Veterinary Products
• Elanco Animal Health
• Kindred Biosciences
• Nextmune (Vimian)
• Phibro Animal Health Corporation
• Toray Industries
• Vetoquinol
• Virbac
• Zoetis
   

Zoetis

Zoetis is a leading player in the canine atopic dermatitis market, holding a dominant share of 22.4% due to its innovative dermatology portfolio, including monoclonal antibodies like Lokivetmab. The company leverages strong global veterinary distribution networks, extensive R&D capabilities, and brand recognition to drive product adoption and maintain market leadership.
 

Elanco Animal Health

Elanco Animal Health plays a significant role in the market through its diversified companion animal dermatology portfolio and targeted therapies. Strategic partnerships, acquisitions, and robust veterinary networks enable Elanco to expand reach and improve access to advanced treatment options.
 

Virbac

Virbac contributes to market growth with its specialized dermatology products and focus on skin health solutions for dogs. The company’s strong presence in Europe and emerging markets, along with close collaboration with veterinary professionals, enhances treatment adoption and strengthens its competitive position.
 

Canine Atopic Dermatitis Industry News

• In December 2025, Elanco Animal Health Incorporated announced its entry into the rapidly expanding canine dermatology market with the U.S. Department of Agriculture (USDA) approval of Befrena (tirnovetmab), a novel anti-IL31 monoclonal antibody (mAb) injection designed to treat canine allergic and atopic dermatitis. This approval enhanced the company’s dermatology portfolio and strengthened its presence in the companion animal therapeutics market.
   
• In September 2024, Elanco Animal Health Incorporated announced that the U.S. Food and Drug Administration (FDA) approved Zenrelia, a safe and highly effective once-daily oral JAK inhibitor designed to control pruritus (itching) associated with allergic dermatitis and manage atopic dermatitis in dogs aged 12 months or older. The approval allowed the company to expand its product portfolio and strengthen its position in the growing canine dermatological treatment market.
   
• In June 2023, Zoetis announced that the U.S. Food and Drug Administration (FDA) approved Apoquel Chewable (oclacitinib chewable tablet) for managing pruritus associated with allergic dermatitis and controlling atopic dermatitis in dogs aged 12 months and older. This approval strengthened Zoetis’ dermatology portfolio, expanded treatment options for veterinarians, and is expected to drive increased sales and market share in the canine atopic dermatitis segment.
   

The canine atopic dermatitis market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• MAbs
• Other products

Market, By Route of Administration

• Oral
• Topical
• Injectable

Market, By Distribution Channel

• Retail pharmacies
• Veterinary hospital pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE